Basic Clinical And Therapeutic Aspects Of Alzheimer S And Parkinson S Diseases

This two-volume work contains the full text of the oral and poster presentations and the general discussion at the round table discussion of the Second International Conference on Alzheimer's and Parkinson's Diseases: Basic and Therapeutic Strategies, held at the Kyoto Park Hotel in Kyoto, Japan, on November 6-10, 1989. The First Conference was held at the Aviya Sonesta Hotel in Eilat, Israel, on March 24-27, 1985. The record of this First Conference was published by Plenum Press in 1986 as Volume 29 in Advances in Behavioral Biology, under the title "Alzheimer's and Parkinson's Diseases: Strategies for Research and Development." We are happy that the comprehensive texts of the oral and poster presentations of the Second Conference could again be published within the framework of this series. Since the First Conference in 1985, rapid progress has been made in both basic and 'therapeutic aspects of these diseases. About 700 scientists from allover the world participated in the Second Conference, and 300 papers were presented in oral and poster sessions. Many people and organizations have helped to organize this multi disciplinary international conference and hence have contributed to the scientific quality of these two volumes. We thank the members of the organizing committee, the organizations that provided financial support, and the contributing scientists for their enthusiastic participation. These two volumes follow the same publishing philosophy as the volume derived from the First Conference. They span a broad spectrum of topics and bridge preclinical and clinical concepts related to these diseases.

This two-volume work contains the full text of the oral and poster presentations and the general discussion at the round table discussion of the Second International Conference on Alzheimer's and Parkinson's Diseases: Basic and Therapeutic Strategies, held at the Kyoto Park Hotel in Kyoto, Japan, on November 6-10, 1989. The First Conference was held at the Aviya Sonesta Hotel in Eilat, Israel, on March 24-27, 1985. , The record of this First Conference was published by Plenum Press in 1986 as Volume 29 in Advances in Behavioral Biology, under the title "Alzheimer's and Parkinson's Diseases: Strategies for Research and Development." We are happy that the comprehensive texts of the oral and poster presentations of the Second Conference could again be published within the framework of this series. Since the First Conference in 1985, rapid progress has been made in both basic and therapeutic aspects of these diseases. About 700 scientists from allover the world participated in the Second Conference, and 300 papers were presented in oral and poster sessions. Many people and organizations have helped to organize this multi disciplinary international conference and hence have contributed to the scientific quality of these two volumes. We thank the members of the organizing committee, the organizations that provided financial support, and the contributing scientists for their enthusiastic participation.

This comprehensive reference provides a detailed overview of current concepts regarding the cause of Parkinson's disease-emphasizing the issues involved in the design, implementation, and analysis of epidemiological studies of parkinsonism.

Alzheimer’s disease (AD) is a devastating and dehumanizing illness affecting increasingly large numbers of elderly and even middle-aged persons in a worldwide epidemic. Alzheimer’s Disease: A Physician’s Guide to Practical Management was written by selected clinicians and scientists who represent some of the world’s leading centers of excellence in AD research. The editors are proud and grateful for their profound contributions. This book is particularly designed to assist physicians and other health-care professionals in the evaluation, assessment, and treatment of individuals with AD. At the same time, by illuminating the basic scientific background, we hope to provide state-of-the art information about the disease and possible future therapeutic strategies. The recent psychiatric treatment aspects of AD are also clearly presented. Because the early diagnosis of the dementia process is now considered of increasing importance, we focus particularly in several chapters on early changes and preclinical conditions, such as mild cognitive impairment and predementia AD.

Alzheimer's disease is a primary neurodegenerative disease whose incidence and prevalence is rapidly approaching epidemic proportions. A major reason for this is that man is living longer than he has ever lived before and the likelihood of contracting the disease is significantly greater within the elderly portion of the population. The problem becomes even more acute in the light of recent estimates which predict that the number of people living beyond the age of 65 is expected to continue to increase. The impact of these statistics on the family and the health care industry in terms of time, effort and cost are staggering. A recent report issued by the Michigan Task Force on Alzheimer's Disease and Related Conditions (1987) effectively underscores this last point. "Each person with a dementing disease requires an average of seven years of care, either at home or in a residential care facility. Care provided at home is estimated to cost about $12,000 annually, for a total of $84,000 per person. This is a conservative figure, however, because many persons with dementia spend their last few years in a nursing home at an average 'cost of $22,000 per year, and some spend from 10 to 15 years in a nursing home, for a total cost of $220,000 to $330,000.

Provides a timely overview of critical advances in molecular and cellular neurobiology, covers key methodologies driving progress, and highlights key future directions for research on neuronal injury and neurodegeneration relevant to neuronal brain pathologies. The editors bring together contributions from internationally recognized workers in the field to provide an up to date account of how and why molecular and cellular neurobiology is such an important area for clinical neuroscience. Understanding the molecular aspects of a number of neurodegenerative conditions such as Parkinson's or Alzheimer's disease for the purpose of improving patient management remains a major challenge of neurobiology be it from the basic or clinical perspective. A strategic evaluation of research contributions and the power of modern methods will help advance knowledge over the next years.

Expert clinicians and basic scientists with a special interest in Parkinson’s disease review the current state of science and clinical therapeutics of the disease. Therefore these articles represent an authorative review of the current state of knowledge regarding preclinical course and symptomatology, subtypes with their impact on the pathology, genetic alterations, novel mechanisms of neuronal cell death, diagnostic tools and old and novel therapeutic approaches with respect to neuroprotection and neuroregeneration in Parkinson’s disease. Particular emphasis has been placed on a novel antiparkinsonian drug called budipine with various modes of action also influencing altered non dopaminergic systems in Parkinson’s disease. It is evident, that many questions on the cause, course and treatment of Parkinson’s disease are still unanswered and therefore the ideal way to treat a parkinsonian patient remains to be defined.